Abstract 1135P
Background
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine cancer of the skin, characterized by a high propensity for metastasis and a dismal prognosis particularly for advanced tumor stages. Immune-checkpoint blockade (ICB) is effective in MCC, but 60% of patients show primary or acquired resistance. Predictive biomarkers for the risk of metastasis and response to ICB are lacking. We studied the tumor microenvironment (TME) of 60 MCC patients to identify molecular mechanisms associated with response to ICB and profile the temporal dynamics occurring during tumor progression.
Methods
We collected 115 tissue biopsies from this MCC cohort with detailed clinical documentation and longitudinal follow-up and profiled the TME with high-plex imaging and matched bulk RNAseq that was collected from consecutive sections using laser-capture microdissection. We integrated clinical and molecular data and explored biomarkers using a lasso regressed CoxPH model.
Results
Our multi-modal data integration framework identified Merkel cell polyomavirus positivity, the abundance of CD8+ T cells and PD-L1+ macrophages as independent determinants of metastasis-free survival (DMFS), while the enrichment of cancer-associated fibroblasts at the tumor boundary correlated with distant metastasis. Response to ICB was correlated with the presence of central memory T cells (TCM), and Follicle-like cellular neighborhoods as well as a PD-L1+ tumor phenotype, that associated with an inflammatory macrophage signature (CXCL9, CXCL10, CXCL13) specifically at the tumor invasive front. By contrast, ICB failure associated with a cancer-stem phenotype (SOX2, NELL) and the downregulation of type-II interferon signaling (STAT1, JAK1). Last, we identified that exacerbation of T cell exhaustion, loss of TCM and inflammatory macrophages are critical elements of MCC evolutionary progression.
Conclusions
We demonstrate that high dimensional imaging of the MCC TME provides a framework to interrogate cellular interactions and tissue architecture in-situ at single-cell resolution. This framework enabled to identify genomic and phenotypic correlates for distant metastasis and response to ICB and map evolutionary changes during tumor progression.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Deutsche Forschungsgemeinschaft.
Disclosure
G. Nolan: Financial Interests, Personal, Stocks or ownership: Akoya Bio. All other authors have declared no conflicts of interest.
Resources from the same session
1091P - Neoadjuvant cemiplimab for stage II–IV cutaneous squamous cell carcinoma (CSCC): 2-year follow-up and biomarker analyses
Presenter: Danny Rischin
Session: Poster session 04
1092P - Nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable melanoma: 3-year subgroup analyses from RELATIVITY-047
Presenter: Dirk Schadendorf
Session: Poster session 04
1093P - Preliminary biomarker analysis in the phase III PIVOTAL study: Evidence for the mechanism of action of daromun in melanoma
Presenter: Paolo Ascierto
Session: Poster session 04
1094P - NeoRisk: Neoadjuvant immunotherapy (NeoIT) recurrence risk assessment tool
Presenter: Ines Pires da Silva
Session: Poster session 04
1095P - Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial
Presenter: Alexander Eggermont
Session: Poster session 04
1096P - Camrelizumab plus apatinib in patients with advanced mucosal melanoma: A 3-year survival update with biomarker analysis
Presenter: Zhengyun Zou
Session: Poster session 04
1098P - Mechanisms of recurrence following mRNA-4157 (V940) plus pembrolizumab or pembrolizumab alone in resected melanoma from the mRNA-4157-P201 (KEYNOTE-942) trial
Presenter: Ryan Sullivan
Session: Poster session 04
1099P - COMBI-EU: Adverse event management of adjuvant dabrafenib plus trametinib (D+T) in patients with BRAF V600-mutant melanoma
Presenter: Peter Mohr
Session: Poster session 04
1100P - Anti-PD1 + low-dose anti-CTLA4 immunotherapy pathological response rate in patients with stage III resectable melanoma: Phase III NEOMIMAJOR trial interim analysis
Presenter: Igor Samoylenko
Session: Poster session 04